Drug Profile
RNS 60
Alternative Names: Oxygenated saline; RNS60Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Queens University; Revalesio
- Developer Revalesio; Rush University
- Class Anti-ischaemics; Antiasthmatics; Antidementias; Antiparkinsonians; Neuroprotectants; Vascular disorder therapies
- Mechanism of Action G protein-coupled receptor modulators; HSP90 heat-shock protein modulators; Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis; Asthma; Multiple sclerosis; Stroke
- Preclinical Alzheimer's disease; Parkinson's disease; Traumatic brain injuries
- Discontinued Myocardial infarction